Sign in
BI

Biofrontera Inc. (BFRI)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 delivered 15% YoY revenue growth to $9.03M on higher price (+5%) and higher Ameluz volume (+9.5%), but losses widened due to elevated legal expense; Adjusted EBITDA was $(5.1)M and net loss was $(5.3)M .
  • Mix and structural COGS tailwinds are material: the new royalty model (12–15% of net sales vs prior 25–35% transfer price) plus manufacturing control is expected to lift gross profit “quite substantially” from Q3 onward, while Q2 already showed higher gross margin vs last year .
  • Q2 results beat revenue consensus but missed EPS: $9.03M vs $8.30M (beat) and $(0.57) vs $(0.39) (miss). Management does not plan a 2025 price increase; SG&A should normalize lower after a Q2 legal spike, improving operating trajectory into 2H25 .
  • Strategic catalysts: US rights acquisition from Biofrontera AG and $11M financing, sBCC FDA submission targeted for 2H25, peripheral AK and acne readouts targeted originally for Q4’25 (acne later updated to Q1’26 in an Aug 25 PR). These events frame the setup for estimate revisions and stock catalysts into 2H25/early 2026 .

What Went Well and What Went Wrong

  • What Went Well

    • Revenue growth from both price and volume: +15% YoY on +5% ASP and +9.5% Ameluz volume; “two very gratifying quarters” driven by segmentation and data-enhanced sales execution .
    • Structural COGS improvement underway: shift to 12–15% royalty (from 25–35% transfer price), manufacturing control and prior transfer-price reductions support substantial gross margin expansion ahead .
    • Commercial KPIs strengthening: 40 RhodoLED XL lamps placed YTD (18 in Q2) with >700 lamps in market; CMS MUE now supports up to 3 Ameluz tubes per treatment, potentially expanding treatment scope and throughput .

  • What Went Wrong

    • Profitability still negative: Q2 net loss of $(5.3)M and Adjusted EBITDA of $(5.1)M, reflecting elevated legal costs and operating expense levels .
    • SG&A spiked on legal: $10.5M in Q2 vs $7.9M last year (+$3.4M legal), masking COGS progress; management expects SG&A to normalize in 2H25 .
    • Timing risks on R&D/milestones: call guided acne and peripheral AK data for Q4’25, later updated post-call to acne topline in Q1’26 (introducing potential model timing shifts) .

Financial Results

MetricQ2 2024Q4 2024Q1 2025Q2 2025
Revenue ($M)$7.84 $12.56 $8.59 $9.03
Net Income (Loss) ($M)$(0.26) $(1.40) $(4.20) $(5.32)
Diluted EPS ($)$(0.05) $(0.19) $(0.47) $(0.57)
Total Operating Expenses ($M)$12.91 $14.27 $13.14 $14.11
Adjusted EBITDA ($M)$(4.73) $(1.38) $(4.38) $(5.14)
Adjusted EBITDA Margin (%)(60.3%) (10.9%) (51.0%) (56.9%)
  • Revenue drivers: +5% ASP, +9.5% Ameluz volume; lamps contributed as well .
  • COGS tailwind: cost of revenues decreased $1.7M YoY (−41.8%), reflecting prior transfer-price renegotiation tied to clinical cost assumption .

Actual vs. Wall Street Consensus (S&P Global)

MetricQ2 2025 ActualQ2 2025 ConsensusSurprise
Revenue ($M)$9.03 $8.30*Beat
EPS ($)$(0.57) $(0.39)*Miss

*Values retrieved from S&P Global.

Balance Sheet (selected)

  • Cash & Cash Equivalents: $7.24M at 6/30/25 vs $5.91M at 12/31/24 and $1.79M at 3/31/25 .
  • Convertible notes payable (net): $4.34M at 6/30/25; advance from stockholders $8.5M, reflecting first tranche of $11M financing; second $2.5M tranche expected in Q3’25 .

KPIs and Commercial Indicators

KPIQ1 2025Q2 2025Notes
Ameluz tubes sold (H1 cumulative)—>50,000 First time >50k in H1 per CEO
RhodoLED XL placements (quarter)22 18 40 XL YTD
Installed lamp base (cumulative)—>700 Leading indicator for growth
CMS MUE (tubes reimbursed per treatment)—Up to 3 tubes listed as of July Supports larger-area treatments
2025 price increase—No increase planned Contrast to ~5% hike last year
Unit price YoY (Q2)—+5% Q2 driver

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Gross Margin2H 2025 onwardN/A“Should increase quite substantially” under 12–15% royalty vs prior 25–35% transfer price Raised (qualitative)
SG&A (legal)Q3–Q4 2025N/AQ2 legal was a spike; SG&A run-rate to be “more in line with historical” in Q3–Q4 Lowered (qualitative)
PriceFY 2025Historically ~annual increase in Q4No price increase planned in 2025 Lowered
Clinical: sBCC FDA submission2H 2025N/ASubmission targeted in 2H25 New timing clarity
Clinical: Peripheral AK toplineQ4 2025N/AData expected Q4’25 (call) New timing
Clinical: Acne toplineQ4 2025 (call)N/AUpdated post-call: topline in Q1 2026 Slipped (post Q2 update)
Revenue/OpEx/Tax/OI&EFY/Q3–Q4 2025N/ANo formal numerical guidance provided—

Earnings Call Themes & Trends

TopicQ4 2024 (Q-2)Q1 2025 (Q-1)Q2 2025 (Current)Trend
Margin structure/COGSTransfer price cut to 25% on 2024 year-end purchases First quarter with lower related-party COGS Move to 12–15% royalty; “substantial” gross margin uplift ahead Improving
SG&A/Legal cadenceLegal normalized vs 2023 in Q4 SG&A down YoY; some legal costs Q2 legal spike; normalize lower in 2H Near-term easing
Lamp expansion100 XL placements by YE’24 XL launch contributing 40 XL YTD; >700 installed Positive
ReimbursementFDA approval to use up to 3 tubes (FY24) —CMS MUE lists up to 3 tubes as of July Supportive
Label expansion (sBCC)Stat sig Phase 3 sBCC results —FDA submission targeted 2H25 Advancing
Label expansion (Body AK)Accelerated recruitment Final patient enrolled Q1’25 Data Q4’25 (call) Near-term readout
Acne programAccelerated recruitment Phase 2b enrollment complete Q1’25 Call: Q4’25 data; PR update: Q1’26 topline Timing extended post-call
PricingQ4’24 price increase noted —No 2025 price increase Neutral-to-slight headwind

Management Commentary

  • “We have changed our approach…transforming our customer segmentation, focusing our strategy and using extended data analysis…This led to two very gratifying quarters…resulting in increased sales volume and higher revenues.” — CEO Hermann Luebbert .
  • “The agreement includes the transfer of all rights…We will pay a monthly Ameluz royalty of 12%…replaces the former transfer pricing model…This will give us further savings on our cost of goods.” — CEO Hermann Luebbert .
  • “Our cost of goods sold and therefore our gross profit should increase quite substantially as a result of this most recent transaction.” — CFO Fred Leffler .
  • “We placed 40 RhodoLED XL lamps [YTD]…lamp placements are the leading indicator for future growth and we now have more than 700 out in doctors’ offices.” — CEO Hermann Luebbert .
  • “Legal expenses…spiked in Q2…should come down and our SG&A run rate should be much more in line with historical amounts Q3 and Q4.” — CFO Fred Leffler .

Q&A Highlights

  • Lamp placements and installed base: 22 XL in Q1 and 18 in Q2 (40 YTD); >700 total lamps in market; 9 small lamps shipped YTD .
  • Pricing: No 2025 price increase, contrasting with prior-year hike .
  • Competitive dynamics: Conversions from Levulan typically involve dual use initially; Levulan ~80% on face/scalp vs arms; Ameluz limited to face/scalp until label expansion .
  • Margin and SG&A cadence: Gross margin uplift expected from royalty model; Q2 legal costs are lumpy/spike and expected to normalize in 2H .
  • Pipeline timing: sBCC FDA submission 2H25; acne and peripheral AK data targeted for Q4’25 on the call, with acne later updated post-call to Q1’26 topline .

Estimates Context

  • Q2 2025 comparison: Revenue $9.03M vs $8.30M consensus (beat); EPS $(0.57) vs $(0.39) consensus (miss). One to two estimates contributed to consensus; Adjusted EBITDA actual $(5.05)M . Consensus values marked with an asterisk are from S&P Global.
  • Forward setup: Consensus embeds a sequential dip in Q3 revenue to ~$7.00M and a sharp rebound in Q4 to ~$15.54M, with EPS of $(0.56) in Q3 and $0.10 in Q4*. Given management’s qualitative gross margin improvement and SG&A normalization, estimate models may need to raise gross margin assumptions, while revenue cadence remains without formal guidance .

Forward Consensus Snapshots (S&P Global)

MetricQ3 2025Q4 2025
Revenue Consensus Mean ($M)$7.00*$15.54*
Primary EPS Consensus Mean ($)$(0.56)*$0.10*

*Values retrieved from S&P Global.

Key Takeaways for Investors

  • Structural gross margin inflection: The royalty model (12–15%) and manufacturing control provide a durable COGS reset vs prior 25–35% transfer pricing, underpinning medium-term margin expansion .
  • Operating leverage potential: SG&A should normalize after Q2’s legal spike, improving EBITDA trajectory as revenue grows off a larger lamp installed base and improved sales execution .
  • Revenue momentum with mix support: Higher ASPs and volume drove Q2 growth; CMS MUE up to 3 tubes per treatment can facilitate broader treatment areas and throughput ahead .
  • Pipeline-driven optionality: sBCC FDA submission in 2H25 and body AK/acne readouts over the next 6–9 months (acne updated to Q1’26) create multiple catalysts; successful label expansions would expand TAM and utilization per patient .
  • Estimates likely to recalibrate: Expect upward revisions to gross margin assumptions and potentially SG&A run-rate; revenue path lacks explicit guidance, so sell-side dispersion may persist*.
  • Liquidity/financing: $7.2M cash at Q2-end and $11M financing (first tranche booked; second $2.5M expected in Q3) support execution of the AG asset transfer and operational independence .
  • Trading setup: Near-term stock drivers include tangible gross margin improvement in Q3/Q4 prints, SG&A normalization, and regulatory/data milestones (sBCC submission; body AK/acne readouts), with downside risk from litigation costs and any slippage in milestone timing .

Notes:

  • All company financials and commentary cited from Biofrontera’s Q2 2025 press release and 8-K, the Q2 2025 earnings call transcript, and related press releases .
  • Consensus estimates marked with an asterisk (*) are retrieved from S&P Global.